Identification of internalizing human single-chain antibodies targeting brain tumor sphere cells

Molecular Cancer Therapeutics

Volumn 9, Issue 7, 2010, Pages 2131-2141

  Zhu, Xiaodong ^a   Bidlingmaier, Scott ^a   Hashizume, Rintaro ^a   James, C David ^a,b   Berger, Mitchel S ^a,b   Liu, Bin ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD133 ANTIGEN; IMMUNOGLOBULIN G1; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; EPITOPE; GLYCOPROTEIN; IMMUNOGLOBULIN FRAGMENT; IMMUNOGLOBULIN G; LEUKOCYTE ANTIGEN; PEPTIDE; PEPTIDE LIBRARY;

ANTIGEN BINDING; ANTIGEN EXPRESSION; ARTICLE; CELL GROWTH; CELL ISOLATION; CELL PROLIFERATION; CELL RENEWAL; CELL SUBPOPULATION; CELL TYPE; CONTROLLED STUDY; GENE IDENTIFICATION; GLIOBLASTOMA; GLYCOSYLATION; HUMAN; HUMAN CELL; MOLECULAR CLONING; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN TARGETING; TUMOR CELL; TUMOR GROWTH; TUMOR SPHERE CELL; ANIMAL; CACO 2 CELL LINE; CANCER STEM CELL; DRUG EFFECTS; ENDOCYTOSIS; FLOW CYTOMETRY; GENETICS; IMMUNOLOGY; METABOLISM; MOUSE; NUDE MOUSE; PATHOLOGY; PEPTIDE LIBRARY; TUMOR CELL CULTURE;

ANIMALS; ANTIGENS, CD; CACO-2 CELLS; CELL PROLIFERATION; ENDOCYTOSIS; EPITOPES; FLOW CYTOMETRY; GLIOBLASTOMA; GLYCOPROTEINS; HUMANS; IMMUNOGLOBULIN FRAGMENTS; IMMUNOGLOBULIN G; MICE; MICE, NUDE; NEOPLASTIC STEM CELLS; PEPTIDE LIBRARY; PEPTIDES; SINGLE-CHAIN ANTIBODIES; TUMOR CELLS, CULTURED;

EID: 77954593073     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-1059     Document Type: Article

References (50)

1. Krex D, Klink B, Hartmann C, et al. Long-term survival with glioblastoma multiforme. Brain 2007;130:2596-606.
2. Nicholas MK. Glioblastoma multiforme: evidence-based approach to therapy. Expert Rev Anticancer Ther 2007;7:S23-7.
3. Benitez JA, Dominguez-Monzon G, Segovia J. Conventional and gene therapy strategies for the treatment of brain tumors. Curr Med Chem 2008;15:729-42.
4. Chang JE, Khuntia D, Robins HI, Mehta MP. Radiotherapy and radiosensitizers in the treatment of glioblastoma multiforme. Clin Adv Hematol Oncol 2007;5:894-902, 907-15.
5. Reardon DA, Desjardins A, Rich JN, Vredenburgh JJ. The emerging role of anti-angiogenic therapy for malignant glioma. Curr Treat Options Oncol 2008;9:1-22.
6. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001;414:105-11.
7. Pardal R, Clarke MF, Morrison SJ. Applying the principles of stem-cell biology to cancer. Nat Rev Cancer 2003;3:895-902. (Pubitemid 37500174)
8. Dalerba P, Cho RW, Clarke MF. Cancer stem cells: models and concepts. Annu Rev Med 2007;58:267-84.
9. Eyler CE, Rich JN. Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol 2008;26:2839-45.
10. Jiang X, Zhao Y, Smith C, et al. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia 2007;21:926-35.
11. Sims AH, Howell A, Howell SJ, Clarke RB. Origins of breast cancer subtypes and therapeutic implications. Nat Clin Pract Oncol 2007;4:516-25.
12. Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003;63:5821-8.
13. Singh SK, Clarke ID, Hide T, Dirks PB. Cancer stem cells in nervous system tumors. Oncogene 2004;23:7267-73.
14. Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature 2004;432:396-401.
15. Yuan X, Curtin J, Xiong Y, et al. Isolation of cancer stem cells from adult glioblastoma multiforme. Oncogene 2004;23:9392-400.
16. Bidlingmaier S, Zhu X, Liu B. The utility and limitations of glycosylated human CD133 epitopes in defining cancer stem cells. J Mol Med 2008;86:1025-32.
17. Lee J, Kotliarova S, Kotliarov Y, et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 2006;9:391-403.
18. Nielsen UB, Marks JD. Internalizing antibodies and targeted cancer therapy: direct selection from phage display libraries. Pharm Sci Technol Today 2000;3:282-91.
19. Liu B. Exploring cell type-specific internalizing antibodies for targeted delivery of siRNA. Brief Funct Genomic Proteomic 2007;6:112-9.
20. Poul MA, Becerril B, Nielsen UB, Morisson P, Marks JD. Selection of tumor-specific internalizing human antibodies from phage libraries. J Mol Biol 2000;301:1149-61.
21. Becerril B, Poul MA, Marks JD. Toward selection of internalizing antibodies from phage libraries. Biochem Biophys Res Commun 1999;255:386-93.
22. Liu B, Conrad F, Cooperberg MR, Kirpotin DB, Marks JD. Mapping tumor epitope space by direct selection of single-chain Fv antibody libraries on prostate cancer cells. Cancer Res 2004;64:704-10.
23. Roth A, Drummond DC, Conrad F, et al. Anti-CD166 single chain antibody-mediated intracellular delivery of liposomal drugs to prostate cancer cells. Mol Cancer Ther 2007;6:2737-46.
24. An F, Drummond DC, Wilson S, et al. Targeted drug delivery to mesothelioma cells using functionally selected internalizing human single-chain antibodies. Mol Cancer Ther 2008;7:569-78.
25. Bidlingmaier S, He J, Wang Y, et al. Identification of MCAM/CD146 as the target antigen of a human monoclonal antibody that recognizes both epithelioid and sarcomatoid types of mesothelioma. Cancer Res 2009;69:1570-7.
26. Ruan W, Sassoon A, An F, Simko JP, Liu B. Identification of clinically significant tumor antigens by selecting phage antibody library on tumor cells in situ using laser capture microdissection. Mol Cell Proteomics 2006;5:2364-73.
27. Giannini C, Sarkaria JN, Saito A, et al. Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme. Neuro Oncol 2005;7:164-76.
28. Kabos P, Ehtesham M, Kabosova A, Black KL, Yu JS. Generation of neural progenitor cells from whole adult bone marrow. Exp Neurol 2002;178:288-93.
29. Westhoff MA, Zhou S, Bachem MG, Debatin KM, Fulda S. Identification of a novel switch in the dominant forms of cell adhesionmediated drug resistance in glioblastoma cells. Oncogene 2008;27:5169-81.
30. O'Connell D, Becerril B, Roy-Burman A, Daws M, Marks JD. Phage versus phagemid libraries for generation of human monoclonal antibodies. J Mol Biol 2002;321:49-56.
31. Sheets MD, Amersdorfer P, Finnern R, et al. Efficient construction of a large nonimmune phage antibody library: the production of high-affinity human single-chain antibodies to protein antigens. Proc Natl Acad Sci U S A 1998;95:6157-62.
32. Liu B, Marks JD. Applying phage antibodies to proteomics: selecting single chain Fv antibodies to antigens blotted on nitrocellulose. Anal Biochem 2000;286:119-28.
33. Liu B, Huang L, Sihlbom C, Burlingame A, Marks JD. Towards proteome-wide production of monoclonal antibody by phage display. J Mol Biol 2002;315:1063-73.
34. Liu B, Conrad F, Roth A, et al. Recombinant full-length human IgG1s targeting hormone-refractory prostate cancer. J Mol Med 2007;85:1113-23.
35. Nowakowski A, Wang C, Powers DB, et al. Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc Natl Acad Sci U S A 2002;99:11346-50.
36. Dallas NA, Xia L, Fan F, et al. Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. Cancer Res 2009;69:1951-7.
37. Pandita A, Aldape KD, Zadeh G, Guha A, James CD. Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR. Genes Chromosomes Cancer 2004;39:29-36.
38. Li C, Heidt DG, Dalerba P, et al. Identification of pancreatic cancer stem cells. Cancer Res 2007;67:1030-7.
39. Weiner LM, Dhodapkar MV, Ferrone S. Monoclonal antibodies for cancer immunotherapy. Lancet 2009;373:1033-40.
40. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol 2005;23:1147-57.
41. Altaner C. Glioblastoma and stem cells. Neoplasma 2008;55:369-74.
42. Thurber GM, Schmidt MM, Wittrup KD. Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv Drug Deliv Rev 2008;60:1421-34.
43. Adams GP, Schier R, McCall AM, et al. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res 2001;61:4750-5.
44. Adams GP, Tai MS, McCartney JE, et al. Avidity-mediated enhancement of in vivo tumor targeting by single-chain Fv dimers. Clin Cancer Res 2006;12:1599-605.
45. Juweid M, Neumann R, Paik C, et al. Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier. Cancer Res 1992;52:5144-53.
46. Ackerman ME, Pawlowski D, Wittrup KD. Effect of antigen turnover rate and expression level on antibody penetration into tumor spheroids. Mol Cancer Ther 2008;7:2233-40.
47. Sundaresan G, Yazaki PJ, Shively JE, et al. 124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice. J Nucl Med 2003;44:1962-9.
48. Calabrese C, Poppleton H, Kocak M, et al. A perivascular niche for brain tumor stem cells. Cancer Cell 2007;11:69-82. (Pubitemid 46054518)
49. Veeravagu A, Bababeygy SR, Kalani MY, Hou LC, Tse V. The cancer stem cell-vascular niche complex in brain tumor formation. Stem Cells Dev 2008;17:859-67.
50. He J, Wang Y, Feng J, et al. Targeting prostate cancer cells in vivo using a rapidly internalizing novel human single-chain antibody fragment. J Nucl Med 2010;51:427-32.